The stock of Lion Biotechnologies Inc (NASDAQ:LBIO) is a huge mover today! The stock increased 4.57% or $0.36 during the last trading session, hitting $8.23. About 256,678 shares traded hands or 3.54% up from the average. Lion Biotechnologies Inc (NASDAQ:LBIO) has risen 47.38% since February 26, 2016 and is uptrending. It has outperformed by 36.95% the S&P500.
The move comes after 6 months positive chart setup for the $476.82 million company. It was reported on Oct, 1 by Barchart.com. We have $23.62 PT which if reached, will make NASDAQ:LBIO worth $891.65 million more.
Analysts await Lion Biotechnologies Inc (NASDAQ:LBIO) to report earnings on November, 3. They expect $-0.21 EPS, down 31.25% or $0.05 from last year’s $-0.16 per share. After $-0.23 actual EPS reported by Lion Biotechnologies Inc for the previous quarter, Wall Street now forecasts -8.70% EPS growth.
According to Zacks Investment Research, “Lion Biotechnologies, Inc. is developing autologous cell therapies for the treatment of cancer. The Company’s lead product candidate, C?ntego(TM), is an autologous cell therapy indicated for the treatment of metastatic melanoma. Lion Biotechnologies, Inc., formerly known as Genesis Biopharma, Inc., is based in Woodland Hills, California.”
Insitutional Activity: The institutional sentiment increased to 1.67 in 2016 Q2. Its up 0.34, from 1.33 in 2016Q1. The ratio improved, as 9 funds sold all Lion Biotechnologies Inc shares owned while 18 reduced positions. 9 funds bought stakes while 36 increased positions. They now own 42.74 million shares or 16.40% more from 36.71 million shares in 2016Q1.
Alliancebernstein Ltd Partnership accumulated 39,600 shares or 0% of the stock. Blackrock Fund Advsr last reported 0% of its portfolio in the stock. Rhumbline Advisers, a Massachusetts-based fund reported 52,276 shares. Moreover, Ghost Tree Capital Lc has 1.64% invested in Lion Biotechnologies Inc (NASDAQ:LBIO) for 700,000 shares. Amer Intl Group Incorporated accumulated 0% or 26,208 shares. New York State Common Retirement Fund reported 41,200 shares or 0% of all its holdings. Geode Management Ltd Company owns 323,355 shares or 0% of their US portfolio. The Pennsylvania-based Nationwide Fund Advsr has invested 0% in Lion Biotechnologies Inc (NASDAQ:LBIO). Moreover, Schwab Charles Mngmt has 0% invested in Lion Biotechnologies Inc (NASDAQ:LBIO) for 159,377 shares. Blackrock Limited owns 13,172 shares or 0% of their US portfolio. Parametric Portfolio Assocs Limited Liability Co, a Washington-based fund reported 38,869 shares. Quantitative Systematic Strategies Ltd Llc accumulated 22,452 shares or 0.08% of the stock. Moreover, Qvt Financial Lp has 0.89% invested in Lion Biotechnologies Inc (NASDAQ:LBIO) for 1.60 million shares. Moreover, Royal National Bank Of Canada has 0% invested in Lion Biotechnologies Inc (NASDAQ:LBIO) for 755 shares. Tower Research Ltd Limited Liability Company (Trc) has 179 shares for 0% of their US portfolio.
Insider Transactions: Since August 22, 2016, the stock had 0 buys, and 1 insider sale for $491,740 net activity. The insider Hillsberg Sanford sold $491,740.
More notable recent Lion Biotechnologies Inc (NASDAQ:LBIO) news were published by: Fool.com which released: “Why Lion Biotechnologies Inc. Stock Is Roaring Higher Today” on June 03, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Lion …” published on May 23, 2016, Thestreet.com published: “Lion Biotechnologies: Is This Tiny Biotech Company Ready to Roar?” on June 06, 2016. More interesting news about Lion Biotechnologies Inc (NASDAQ:LBIO) were released by: Marketwatch.com and their article: “/quotes/zigman/3870025/realtime” published on November 20, 2013 as well as Quotes.Wsj.com‘s news article titled: “News Lion Biotechnologies Inc.LBIO” with publication date: August 14, 2014.
LBIO Company Profile
Lion Biotechnologies, Inc., incorporated on September 17, 2007, is a clinical-stage biotechnology company. The Firm is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.